Another Flagship startup takes a direct hit, shedding close to half its staff in latest restructuring
2022-11-04
信使RNA
Another one of Flagship’s biotech startups traveling the edge of the innovation galaxy has run into trouble. And they’ve brought out the budget axe — the tool of first resort in a world where once roaring streams of money have calmed considerably.
Eighteen months after Repertoire Immune Medicines unveiled a whopping $189 million raise, the company confirmed Friday afternoon that it has laid off 65 staffers, or close to half the employee roster.
There’s no word why they’re cutting, though earlier in the week another big Flagship startup, Rubius, pared down to a skeleton crew in search of an exit strategy of some kind. A spokesperson tells Endpoints they’ll have more on the restructuring next week.
FierceBiotech first reported the Repertoire layoffs earlier Friday.
In Rubius’s case, Flagship chief Noubar Afeyan exited the chairman’s role at its second demise — the first iteration went down for the count following weak human data. In Repertoire’s case, Afeyan started as the chairman of the enterprise, a combination of two startups that were exploring the junction of TCRs and antigens.
Repertoire is helmed by John Cox, who helped forge a union of Cogen Immune Medicine and Torque Therapeutics. Pfizer vet Anthony Coyle serves as president and head of R&D, fitting a mold of pharma vets recruited into the Flagship fold.
A few weeks ago, ex-Rubius chair David Epstein — out of Novartis — exited Flagship after a five-year stint.
Flagship led the latest big round at Repertoire, with assistance from Softbank Vision Fund2, the Public Sector Pension Investment Board, the Alaska Permanent Fund, and Invus.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。